Satellite Symposia

Satellite Symposia (SS) are independent educational events held during the Crohn’s & Colitis Congress® and are intended to complement the official scientific program. They offer a unique opportunity to present content before or after Congress sessions and may provide CME/CE credit.The top areas of interest for attendees are Clinical, Research, and Microbiome in Gastrointestinal and Liver Diseases. 

View Guidelines
Submit an Application

Time Slots & Fees

Thursday, January 22, 2026

Two Evening time slots (concurrent)
  • Fee: $30,000
  • Restrictions: May not begin before 6:00 p.m., including registration and F&B service.
  • Room Capacity (with round dining tables and A/V set up): 110

Friday, January 23, 2026

Two Morning time slots (concurrent)
  • Fee: $30,000
  • Restrictions: Must conclude by 7:30 a.m., including any Q&A
  • Room Capacity (with round dining tables and A/V set up): 110
One Lunch time slot
  • Fee: $40,000
  • Restrictions: Must be held between 11:30 a.m. – 2:00 p.m., including registration, F&B service, and Q&A.
  • Room Capacity (with round dining tables and A/V set up): 140

As more information for the Satellite Symposia becomes available this page will be updated. Last updated, September 2025. 

Satellite Symposia Schedule

While you’re at Crohn’s & Colitis Congress® 2026, take advantage of any of the following Satellite Symposia. Please be sure to register for each one separately.

All times listed are listed in Pacific Time. Times and programming are subject to change.  

Thursday, January 22, 2026

The Future Is Anti-Inflammatory: Redefining IBD Outcomes Through Targeting IL-23p19
 
This activity if provided by Med Learning Group. This activity is supported by an educational grant from Lilly.
 
Time: 6 – 7:30 p.m.
Location: Monet 3
 

Faculty

  • Jessica R. Allegretti, MD, MPH, FACG, AGAF
  • Christina Ha, MD, FACG, AGAF
 
The satellite symposium aims to enhance health care professionals’ capacity to utilize evidence regarding the long-term effectiveness of anti-IL23p19 biologics in making clinical decisions for ulcerative colitis (UC) and Crohn’s disease (CD). The symposium will focus on the integration of objective measures, such as endoscopy, histology, and biomarkers, into the assessment of long-term efficacy.  Additionally, the symposium will facilitate the analysis of the comparative value of corticosteroid-free remission, promoting its application in shared decision-making.
Register

Here Come the IL-23p19 Inhibitors: Exploring New Treatments in IBD

In partnership with Lilly, USA.

Join expert faculty, Prof. Vipul Jairath and Dr. Aline Charabaty, as they explore the new and evolving treatment landscape in inflammatory bowel disease (IBD) during interactive, patient case-based discussions.

Learning Objectives:

  • Examine the evolving treatment goals in the management of IBD
  • Interpret the efficacy and safety, including the long-term data for IL-23p19 inhibitors
  • Apply these concepts in case discussions

Faculty

  • Prof. Vipul Jairath
  • Dr. Aline Charabat
Register

Friday, January 23, 2026

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

This activity is supported by an educational grant from Genentech, Inc.

Time: 6 – 7:30 a.m.
Location: Monet 4
 

Faculty

  • Jordan Axelrad, MD, MPH (Chair)
  • Jessica R. Allegretti, MD, MPH, FACG, AGAF
  • Florian Rieder, MD
 
Research revealing that overexpression of TNF-Like Ligand 1A (TL1A) drives key inflammatory pathways in inflammatory bowel disease (IBD) has accelerated the development of biologic therapies aimed at inhibiting this ligand. Early studies of investigational anti-TL1A agents—including tulisokibart, afimkibart, and duvakitug—demonstrate encouraging outcomes in patients with moderate-to-severe IBD, showing improvements in symptoms as well as reductions in chronic intestinal inflammation and fibrosis. This high-impact symposium is tailored to gastroenterology-focused clinicians who are navigating an increasingly dynamic IBD treatment landscape. The symposium will highlight emerging evidence and potential clinical applications of anti-TNF–Like Ligand 1A therapies, featuring expert perspectives on interpreting new data. Through case-based discussions and interactive polling, participants will gain practical, up-to-date strategies to enhance IBD management and remain at the forefront of therapeutic innovation.
Register

A CaseWise™ Initiative—Mission Possible: Matching Treatment Goals of Patients and Providers in IBD in Clinical Practice

This activity is supported by an educational grant from Johnson & Johnson.

Time: 11:30 a.m. – 2 p.m.
Location: Raphael 1/2
 

Faculty

  • Miguel Regueiro, MD (Moderator)
  • Anita Afzali, MD, MPH, MHCM, FACG, AGAF
  • Edward L. Barnes, MD, MPH
  • Angelina Collins, MSN, ANP-BC
 
This fast-paced and highly interactive live CaseWise™ symposium from CME Outfitters will bring real-world clinical decision-making to life. Through dynamic patient cases, learners will compare their treatment choices to those of leading experts, peers in the room, providers in the community, patients themselves, and even AI-based insights. Learners will see how evidence translates into practice, what doesn’t, and why. Designed to challenge assumptions and sharpen strategy, this immersive format empowers clinicians to immediately apply the latest IL-23 inhibitor data, enhance communication and shared decision-making, and deliver truly patient-centered IBD care.
Register

We look forward to working with you and ensuring that you have a positive experience sharing your innovations with our attendees.

Interested in learning more or have additional questions, please contact:

CHLOE STEIN
Senior Coordinator, Industry Sales and Operations 
American Gastroenterological Association 

Chloe Stein

This website uses cookies to provide you with the best experience on our website. If you wish to disable cookies, please do so in your browser settings. Your continued use of our site without disabling your cookies is subject to the cookie policy. Learn More

I agree